Big Ideas Yield Transformative Results for SMA Patients: A conversation with Stuart Peltz, the Founder and CEO of PTC Therapeutics

Breakthrough Therapy

Celebrate SMA Awareness with us!  Stuart Peltz (Founder and CEO, PTC Therapeutics) shares his perspectives on the dynamics of R&D in the context of the journey that led to the accelerated approval this August of  Evrysdi™ (risdiplam), the first oral treatment for SMA. What can we learn from the collaborative partnership between Roche, PTC Therapeutics, and the SMA Foundation?

Subscribe to WXPress

Receive our newsletter and information on upcoming events.